High-throughput screening of clinically approved drugs that prime nonviral gene delivery to human Mesenchymal stem cells

Table 1 Highest fold-changes in transfection priming hits in each donor

	Drug	Drug Class	Concentration [μM]	TE^a	EGFP^b	RLU/mg^c	Viability^d	Hoechst^e
Donor 1	Clobetasol Propionate	Glucocorticoid	1.7	2.1	2.5	31	1.1	1.1
	Dexamethasone	Glucocorticoid	100	2.1	2.6	28	1.2	1.4
	Triamcinolone Acetonide	Glucocorticoid	100	1.8	2.4	21	1.2	1.4
	Fluorometholone	Glucocorticoid	13	2.4	2.8	16	1.2	1.1
	Fluorometholone	Glucocorticoid	100	3.6	4.5	13	1.1	1.2
Donor 2	Beclomethasone dipropionate	Glucocorticoid	13	2.4	2.9	6.9	1.0	1.2
	Fluorometholone	Glucocorticoid	100	2.9	2.7	6.3	0.9	1.0
	Fluocinolone acetonide	Glucocorticoid	1.7	2.4	2.7	6.0	1.0	1.1
	Clobetasol propionate	Glucocorticoid	1.7	3.1	2.5	4.7	1.0	0.9
	Triamcinolone acetonide	Glucocorticoid	1.7	2.5	2.2	5.2	1.0	0.9

^aTE FCs were calculated from triplicate averages of EGFP positive cell-counts normalized to Hoechst-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^bEGFP FCs were calculated from triplicate averages of EGFP positive cell-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^cRLU/mg FCs were calculated from triplicate averages of luciferase luminescence, in relative light units (RLUs), normalized to total protein, relative to the same measurement averaged from the VCs in each compound’s respective plate
^dViability ratios were calculated from triplicate averages of live cell-counts (number of Hoechst stained objects minus number of ethidium stained objects) normalized to Hoechst-counts, relative to the same measurement averaged from the VCs in each compound’s respective plate
^eHoechst ratios were calculated from triplicate averages of total cell-count (determined by Hoechst-count), relative to the same measurement averaged from the VCs in each compound’s respective plate

ISSN: 1754-1611